These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36761917)

  • 21. 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Bonfill Cosp X; Flicker L
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012216. PubMed ID: 29164603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach.
    Royse SK; Minhas DS; Lopresti BJ; Murphy A; Ward T; Koeppe RA; Bullich S; DeSanti S; Jagust WJ; Landau SM;
    Alzheimers Res Ther; 2021 May; 13(1):99. PubMed ID: 33971965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline.
    Pascual-Lucas M; Allué JA; Sarasa L; Fandos N; Castillo S; Terencio J; Sarasa M; Tartari JP; Sanabria Á; Tárraga L; Ruíz A; Marquié M; Seo SW; Jang H; Boada M;
    Alzheimers Res Ther; 2023 Jan; 15(1):2. PubMed ID: 36604729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals.
    Biel D; Brendel M; Rubinski A; Buerger K; Janowitz D; Dichgans M; Franzmeier N;
    Alzheimers Res Ther; 2021 Aug; 13(1):137. PubMed ID: 34384484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Relevance of [
    Librizzi D; Cabanel N; Zavorotnyy M; Riehl E; Kircher T; Luster M; Hooshyar Yousefi B
    Molecules; 2021 Feb; 26(5):. PubMed ID: 33652938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Associations between white matter microstructure and amyloid burden in preclinical Alzheimer's disease: A multimodal imaging investigation.
    Racine AM; Adluru N; Alexander AL; Christian BT; Okonkwo OC; Oh J; Cleary CA; Birdsill A; Hillmer AT; Murali D; Barnhart TE; Gallagher CL; Carlsson CM; Rowley HA; Dowling NM; Asthana S; Sager MA; Bendlin BB; Johnson SC
    Neuroimage Clin; 2014; 4():604-14. PubMed ID: 24936411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.
    Knopman DS; Lundt ES; Therneau TM; Albertson SM; Gunter JL; Senjem ML; Schwarz CG; Mielke MM; Machulda MM; Boeve BF; Jones DT; Graff-Radford J; Vemuri P; Kantarci K; Lowe VJ; Petersen RC; Jack CR;
    JAMA Neurol; 2021 Feb; 78(2):217-228. PubMed ID: 33074304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic impact of [
    Zwan MD; Bouwman FH; Konijnenberg E; van der Flier WM; Lammertsma AA; Verhey FR; Aalten P; van Berckel BN; Scheltens P
    Alzheimers Res Ther; 2017 Jan; 9(1):2. PubMed ID: 28093088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical impact of amyloid PET using
    Matsuda H; Okita K; Motoi Y; Mizuno T; Ikeda M; Sanjo N; Murakami K; Kambe T; Takayama T; Yamada K; Suehiro T; Matsunaga K; Yokota T; Tateishi U; Shigemoto Y; Kimura Y; Chiba E; Kawashima T; Tomo Y; Tachimori H; Kimura Y; Sato N
    Ann Nucl Med; 2022 Dec; 36(12):1039-1049. PubMed ID: 36194355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of early-phase [
    Daerr S; Brendel M; Zach C; Mille E; Schilling D; Zacherl MJ; Bürger K; Danek A; Pogarell O; Schildan A; Patt M; Barthel H; Sabri O; Bartenstein P; Rominger A
    Neuroimage Clin; 2017; 14():77-86. PubMed ID: 28138429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Aβ deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [
    O'Dell RS; Mecca AP; Chen MK; Naganawa M; Toyonaga T; Lu Y; Godek TA; Harris JE; Bartlett HH; Banks ER; Kominek VL; Zhao W; Nabulsi NB; Ropchan J; Ye Y; Vander Wyk BC; Huang Y; Arnsten AFT; Carson RE; van Dyck CH
    Alzheimers Res Ther; 2021 Jan; 13(1):11. PubMed ID: 33402201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Green RC; Harvey D; Jack CR; Jagust W; Luthman J; Morris JC; Petersen RC; Saykin AJ; Shaw L; Shen L; Schwarz A; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2015 Jun; 11(6):e1-120. PubMed ID: 26073027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome.
    Zammit MD; Tudorascu DL; Laymon CM; Hartley SL; Zaman SH; Ances BM; Johnson SC; Stone CK; Mathis CA; Klunk WE; Cohen AD; Handen BL; Christian BT
    Neuroimage; 2021 Mar; 228():117728. PubMed ID: 33421595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [
    Hanseeuw BJ; Malotaux V; Dricot L; Quenon L; Sznajer Y; Cerman J; Woodard JL; Buckley C; Farrar G; Ivanoiu A; Lhommel R
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):302-310. PubMed ID: 32601802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secondary prevention of Alzheimer's dementia: neuroimaging contributions.
    Ten Kate M; Ingala S; Schwarz AJ; Fox NC; Chételat G; van Berckel BNM; Ewers M; Foley C; Gispert JD; Hill D; Irizarry MC; Lammertsma AA; Molinuevo JL; Ritchie C; Scheltens P; Schmidt ME; Visser PJ; Waldman A; Wardlaw J; Haller S; Barkhof F
    Alzheimers Res Ther; 2018 Oct; 10(1):112. PubMed ID: 30376881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline [
    Teng E; Manser PT; Sanabria Bohorquez S; Wildsmith KR; Pickthorn K; Baker SL; Ward M; Kerchner GA; Weimer RM
    Alzheimers Res Ther; 2021 Dec; 13(1):196. PubMed ID: 34852837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging.
    Lopes Alves I; Heeman F; Collij LE; Salvadó G; Tolboom N; Vilor-Tejedor N; Markiewicz P; Yaqub M; Cash D; Mormino EC; Insel PS; Boellaard R; van Berckel BNM; Lammertsma AA; Barkhof F; Gispert JD
    Alzheimers Res Ther; 2021 Apr; 13(1):82. PubMed ID: 33875021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.